在前线免疫化疗后的卵泡淋巴瘤中,高风险定义事件的结果
Joshua W D Tobin1,2, Venkata A Chikatamarla2,3,4, Marko Matic3
1Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Blood neoplasia
|June 24, 2025
概括
毛囊淋巴瘤在24个月内进展 (FL24) 和早期转变 (早期TFL) 是影响整体生存的高风险事件. 区分这些条件对于患者管理和未来的临床试验至关重要.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 毛囊淋巴瘤 (FL) 在免疫化疗 (ICT) 24 个月内进展或转变意味着与整体存活率 (OS) 差相关的高风险定义事件 (HRDE).
- 确定这些HRDE的特定临床和成像特征对于改善患者的治疗结果和指导治疗策略至关重要.
研究的目的:
- 分析初始临床特征,成像特征和新诊断的FL患者经历HRDE的结果.
- 为了比较不同HRDE组之间的总生存期 (OS):24个月内复发或进展 (FL24),早期转变 (<24个月的ICT),以及晚期转变 (>24个月的ICT).
主要方法:
- 对433名新诊断FL需要ICT的患者的回顾性分析,分为参考FL (Ref FL),FL24,早期TFL和晚期TFL组.
- 使用多变量分析对HRDE组和Ref FL组之间的临床特征,成像 (最大标准化摄入值-SUVmax) 和整体存活率 (OS) 的比较.
主要成果:
- 与Ref FL组相比,FL24,早期TFL和晚期TFL组的患者的生存状况明显较差.
- 早期的TFL与FL24相比显示出较低的OS.
- 虽然临床特征没有区分早期TFL和FL24,但SUVmax在早期TFL中比Ref FL更高.
结论:
- 早期TFL和FL24都是不同的HRDE,与毛囊淋巴瘤患者的劣质OS相关.
- 区分早期TFL和FL24对于生物标志物开发,患者管理以及设计和解释临床试验来解决这一未满足的需求至关重要.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.5K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.5K
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:27Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675